← Back to Home

Delivering a Longer Gene in Two Parts: CAN204 Duchenne Muscular Dystrophy Therapy Reports Mouse Results

Dual AAV vectors paired with RNA splicing aim to overcome gene delivery capacity limits. CANbridge reports protection of mouse muscles in repeated contraction tests, but delivery efficiency, safety and durability remain challenges before patient benefit can be demonstrated.

By SURL BioNews

Gene therapy for Duchenne muscular dystrophy (DMD) faces a delivery challenge: the protein to be replaced is very large, while commonly used viral vectors cannot accommodate the complete instructions. On November 2, CANbridge announced mouse study results for its investigational therapy CAN204, which attempts to deliver the instructions separately using two vectors and then join them at the RNA level, enabling muscle cells to produce a longer version of dystrophin.

DMD results from loss-of-function mutations in the gene encoding dystrophin, causing progressive muscle degeneration and weakness. Limited by the packaging capacity of adeno-associated virus (AAV), many AAV therapies use substantially shortened microdystrophin sequences. CAN204 is being developed to explore the possibility of retaining more of the protein’s functional domains despite these capacity constraints.

The technology, called StitchR, uses self-cleaving ribozymes to join RNA precursors delivered by two AAV vectors into a single, longer messenger RNA. According to the company, the platform can support expression of midi-dystrophin sequences up to 7.5 kb long. This is still a shortened version, and whether a longer sequence can deliver better clinical outcomes remains unproven.

In the reported experiments in mdx mice with Duchenne muscular dystrophy, researchers delivered CAN204 using the MYO4A capsid at doses ranging from 5×10¹³ to 2×10¹⁴ vector genomes per kilogram. The company said that after repeated eccentric contraction tests, in which muscles are lengthened while generating force, muscle strength in treated mice reached levels comparable to those of healthy wild-type controls.

The announcement also stated that muscle protection in the MYO4A delivery group exceeded that in the AAVMYO2, AAVMYO3, AAV9 and vehicle control groups. However, these comparisons do not directly establish that CAN204 is superior to other DMD therapies for humans. The company is also still screening capsids for clinical development, and MYO4A has not been confirmed as the final choice for human development.

PharmCube ByDrug republished the same research content that day, but the source remained the company announcement, rather than independent validation by another research group. The announcement did not provide animal numbers, follow-up duration or detailed safety data sufficient for a full assessment of the results. Performance approaching healthy controls in a single muscle strength test also does not mean the disease has been comprehensively corrected or that patients’ walking, breathing and cardiac function will necessarily improve.

CANbridge plans to present the research orally on November 12 at the ASGCT Breakthroughs meeting in Nashville, United States. These results provide animal-study evidence for the dual-vector and RNA-splicing strategy. The next questions are whether the longer protein can be expressed effectively, persistently and safely in humans, and whether this can translate into functional improvements that patients can perceive.

References

  1. CANbridge Pharmaceuticals
  2. PharmCube ByDrug (CANbridge announcement republication)